Semaglutide is a long-acting glucagon-like peptide-1 receptor (GLP-1R) agonist developed from the biology of endogenous GLP-1. It has been extensively investigated for its effects on glucose regulation, food intake, appetite-related behavior, and metabolic physiology.
GLP-1 is an endogenous peptide hormone involved in communication between the gastrointestinal tract, pancreas, brain, and other tissues. Its signaling participates in glucose-dependent insulin secretion, suppression of glucagon under appropriate metabolic conditions, gastrointestinal processes, and regulation of food intake.
Semaglutide was designed to provide prolonged GLP-1 receptor activity compared with native GLP-1. Its biological effects have consequently been investigated across cellular, animal, and human research models.
A substantial body of clinical research has examined semaglutide in people with type 2 diabetes and in people with overweight or obesity. Separate experimental studies have investigated appetite, energy intake, food preference, gastric emptying, and central nervous-system pathways.
Importantly, research findings concerning appetite regulation and changes in body weight should be understood as outcomes observed in specific study populations and experimental conditions, rather than as universal or guaranteed individual effects.
GLP-1 receptor
Semaglutide is a long-acting agonist of the glucagon-like peptide-1 receptor, a class B G-protein-coupled receptor.
Clinical + mechanistic
Evidence includes controlled human trials as well as cellular and physiological research examining GLP-1 signaling.
1. Compound Overview
Semaglutide is a modified peptide based on the structure of human GLP-1. Structural modifications increase resistance to enzymatic degradation and extend circulation time, allowing sustained GLP-1 receptor activation.
GLP-1 receptor signaling is physiologically complex because the receptor is expressed in multiple tissues and participates in several interconnected systems.
Research has therefore examined semaglutide across several domains, including pancreatic hormone secretion, gastrointestinal physiology, appetite, food intake, and central nervous-system signaling.
Semaglutide should be understood as a GLP-1 receptor agonist. Findings from other GLP-1 receptor agonists can provide biological context for the class, but should not automatically be treated as semaglutide-specific evidence.
2. GLP-1 Signaling
GLP-1 is an incretin hormone produced primarily by intestinal enteroendocrine L cells. Its release is influenced by nutrient exposure and gastrointestinal signaling.
After release, GLP-1 interacts with GLP-1 receptors expressed on multiple cell populations. The receptor is a G-protein-coupled receptor capable of activating intracellular signaling pathways involving cyclic AMP and downstream protein kinases.
In pancreatic beta cells, GLP-1 receptor activation contributes to glucose-dependent insulin secretion. GLP-1 signaling can also influence glucagon secretion, gastric function, and neural pathways involved in food intake.
cAMP signaling
The GLP-1 receptor is coupled primarily to Gs-mediated signaling, which increases intracellular cyclic AMP following receptor activation.
This second-messenger system can activate downstream pathways such as protein kinase A and exchange proteins directly activated by cAMP. These pathways contribute to cellular responses associated with GLP-1 receptor activation.
GLP-1R
Semaglutide activates the glucagon-like peptide-1 receptor.
cAMP
Receptor activation increases intracellular second-messenger signaling.
Hormonal Response
GLP-1R signaling influences glucose-dependent pancreatic hormone responses.
Neural Signaling
GLP-1-related signaling participates in pathways involved in appetite and food-intake regulation.
3. The GLP-1 Receptor
The GLP-1 receptor belongs to class B1 G-protein-coupled receptors. It is expressed in tissues involved in metabolic and endocrine regulation, including pancreatic islets and components of the nervous system.
Receptor activation produces intracellular signaling that varies according to cell type, receptor environment, and physiological context.
This is relevant when interpreting semaglutide research because appetite regulation is not produced by a single isolated pathway. Instead, peripheral and central signals interact to influence feeding behavior.
4. Appetite Regulation
One of the most extensively investigated areas of semaglutide research is its relationship with appetite and food intake.
Appetite is regulated through an integrated network involving the gastrointestinal tract, peripheral metabolic signals, hypothalamic circuits, brainstem pathways, and higher-order brain regions involved in reward and food-related behavior.
GLP-1 signaling forms part of this network. Experimental research indicates that GLP-1 receptor activation can influence neural pathways involved in hunger, satiety, food intake, and the motivation to eat.
Hunger and fullness
Controlled human studies have measured subjective appetite-related outcomes during semaglutide treatment. These studies have examined variables including hunger, fullness, prospective food consumption, and overall control of eating.
In a controlled study of adults with obesity, Blundell and colleagues reported changes in appetite-related measures and energy intake during once-weekly semaglutide exposure.
Such findings provide human evidence that appetite-related effects can accompany GLP-1 receptor activation by semaglutide.
Appetite questionnaires and laboratory measurements of food intake provide evidence about specific behavioral and physiological variables. They do not establish that every individual will experience the same appetite-related response.
5. Energy Intake and Food-Related Behavior
Research has investigated whether changes observed during semaglutide exposure are associated with altered energy intake rather than being explained exclusively by changes in energy expenditure.
In controlled experimental research, semaglutide has been associated with reductions in measured food intake in study participants.
Investigators have also examined whether semaglutide changes food preference, perceived control over eating, and responses to food stimuli.
Food preference research
Appetite regulation involves more than the perception of hunger. Food reward, cravings, preference, and the ability to regulate eating behavior are also relevant components.
Experimental human studies have investigated these variables under controlled conditions and have reported changes in several appetite-related measures during semaglutide exposure.
6. Gastric Emptying and Gastrointestinal Signaling
The gastrointestinal tract plays an important role in GLP-1 physiology. GLP-1 receptor activation can influence gastric function and the movement of nutrients through the gastrointestinal system.
Gastric emptying is relevant to appetite research because the rate at which nutrients leave the stomach influences nutrient delivery to the small intestine and can affect post-meal signaling.
Human studies have therefore investigated gastric emptying alongside appetite and energy intake during semaglutide exposure.
Early and sustained effects
Research suggests that the relationship between GLP-1 receptor activation and gastric emptying is not necessarily constant over time. Tachyphylaxis and adaptation of gastrointestinal responses have been investigated in GLP-1 physiology.
This is one reason appetite regulation should not be reduced to a simple model in which semaglutide acts solely by slowing gastric emptying.
7. Glucose and Metabolic Signaling
GLP-1 receptor activation has well-established physiological relevance to glucose regulation.
In pancreatic beta cells, GLP-1 signaling enhances glucose-dependent insulin secretion. GLP-1 receptor activation can also suppress inappropriate glucagon secretion under hyperglycemic conditions.
These effects contribute to the glucose-lowering biology observed with GLP-1 receptor agonists.
Glucose-dependent insulin signaling
An important characteristic of GLP-1 physiology is its dependence on ambient glucose concentrations. GLP-1 receptor signaling amplifies insulin secretion when glucose is elevated rather than functioning as a simple glucose-independent insulin stimulus.
Semaglutide has been extensively investigated in people with type 2 diabetes, where controlled trials have assessed glycemic outcomes alongside other metabolic endpoints.
agonist
activation
signaling
neural responses
8. Clinical Research
Semaglutide has been studied extensively in randomized controlled clinical trials. The SUSTAIN clinical development program evaluated semaglutide in people with type 2 diabetes across multiple trial designs and comparator groups.
The STEP clinical program subsequently examined semaglutide in adults with overweight or obesity without diabetes, with trials evaluating changes in body weight and metabolic health alongside safety and other endpoints.
These large clinical programs provide substantially stronger evidence for semaglutide-specific outcomes than studies involving unrelated GLP-1 receptor agonists.
SUSTAIN-6
In the SUSTAIN-6 cardiovascular outcomes trial, Marso and colleagues evaluated once-weekly semaglutide in adults with type 2 diabetes at elevated cardiovascular risk.
The trial was designed primarily around cardiovascular outcomes and also assessed glycemic and other clinical endpoints.
STEP 1
Wilding and colleagues evaluated once-weekly semaglutide in adults with overweight or obesity in the STEP 1 randomized clinical trial.
The study provided large-scale evidence concerning changes in body weight and cardiometabolic variables under controlled clinical conditions.
Importantly, these clinical findings represent observations in a defined trial population receiving a defined investigational intervention. They should not be converted into promises of a particular outcome for an individual.
Appetite-specific clinical research
Separate controlled studies have examined appetite and energy intake directly. Blundell et al. investigated appetite, food intake, control of eating, and food preference in adults with obesity.
Friedrichsen and colleagues subsequently investigated energy intake, appetite, control of eating, and gastric emptying in adults with overweight or obesity.
Type 2 diabetes
Large clinical development program examining glycemic, cardiovascular, and other metabolic outcomes.
Overweight / obesity
Randomized clinical research evaluating semaglutide in adults with overweight or obesity.
9. Mechanistic Framework: Why Appetite Changes Are Studied
Current research supports a multi-system model of GLP-1 receptor signaling rather than a single mechanism for appetite regulation.
Peripheral gastrointestinal signals, pancreatic endocrine responses, vagal and brainstem pathways, hypothalamic circuits, and higher-order neural systems can all contribute to the regulation of food intake.
agonism
signaling
hypothalamic pathways
food intake
This framework helps explain why studies measure several variables simultaneously. Changes in subjective appetite, food intake, gastric emptying, glucose regulation, and body weight can represent related but distinct physiological outcomes.
10. Central Nervous-System Research
GLP-1 receptors are present in neural circuits involved in energy balance and feeding behavior. Experimental research has therefore examined whether GLP-1 receptor activation alters signaling in brain regions associated with appetite and food reward.
The central effects of GLP-1 receptor agonism are complex because neural GLP-1 signaling interacts with other systems regulating hunger, satiety, reward, and metabolic state.
Semaglutide-specific human studies have investigated subjective appetite and food-related behavior, while broader GLP-1 research provides additional mechanistic context for understanding potential central pathways.
Evidence that GLP-1 signaling participates in neural appetite circuits does not mean that every reported behavioral effect has been demonstrated specifically with semaglutide in every population.
11. What the Published Literature Shows
12. Limitations of the Existing Evidence
Why the literature requires careful interpretation
- Class versus compound evidence: Findings from other GLP-1 receptor agonists should not automatically be attributed to semaglutide.
- Population differences: Results can differ between people with type 2 diabetes and people with overweight or obesity without diabetes.
- Endpoint differences: Appetite scores, measured food intake, gastric emptying, glycemic control, and body weight are distinct endpoints.
- Mechanistic complexity: Appetite regulation involves multiple interacting neural, gastrointestinal, endocrine, and behavioral systems.
- Long-term questions: Ongoing research continues to examine the long-term biological, metabolic, and clinical implications of sustained GLP-1 receptor activation.
- Individual variability: Clinical trial averages describe population-level effects and cannot predict an identical response in every individual.
13. Research Status
Semaglutide is one of the most extensively studied long-acting GLP-1 receptor agonists, with substantial evidence from randomized clinical trials as well as mechanistic and physiological research.
The strongest evidence supports its pharmacological activity at the GLP-1 receptor and its effects on glucose-regulatory physiology. Human research has also directly investigated appetite, food intake, gastric function, and metabolic outcomes.
The precise contribution of each pathway to observed clinical outcomes remains an active research question. Appetite regulation, for example, involves overlapping gastrointestinal, endocrine, and central nervous-system mechanisms rather than one isolated pathway.
14. Conclusion
Semaglutide acts primarily through activation of the GLP-1 receptor, linking it to a broad physiological network involving pancreatic signaling, gastrointestinal function, metabolic regulation, and neural control of food intake.
Research examining appetite provides evidence that semaglutide can alter several measurable aspects of eating behavior and energy intake under controlled experimental conditions. These findings are consistent with the broader biology of GLP-1 signaling, which integrates peripheral nutrient signals with central pathways involved in appetite regulation.
Clinical trials have additionally established a substantial evidence base for semaglutide in metabolic research. However, population-level clinical findings should not be interpreted as guarantees of a particular response for an individual.
The most useful scientific framework is therefore to view semaglutide as a long-acting GLP-1 receptor agonist whose effects emerge from interconnected endocrine, gastrointestinal, metabolic, and neural signaling pathways.
The primary biological target of semaglutide is the GLP-1 receptor. Published research supports a connection between GLP-1R activation, glucose-dependent endocrine signaling, gastrointestinal processes, and measurable changes in appetite and food intake. The relative contribution of each pathway remains an important area of physiological and clinical research.
Scientific research context
This article is provided for scientific and educational research purposes only. Semaglutide is discussed as a subject of published pharmacological and clinical research. The information presented here does not constitute medical advice, treatment recommendations, or instructions for personal use. This review intentionally does not provide dosing, administration, cycling, stacking, procurement, or self-experimentation guidance.
References
The following publications provide primary experimental and clinical evidence relevant to semaglutide pharmacology, GLP-1 signaling, appetite, energy intake, and metabolic outcomes.
- Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015;58(18):7370–7380.
- Kapitza C, Nosek L, Jensen L, et al. Semaglutide, a once-weekly human GLP-1 analogue, does not reduce the bioavailability of ethinylestradiol/levonorgestrel oral contraceptive combination. Journal of Clinical Pharmacology. 2015.
- Blundell J, Finlayson G, Axelsen MB, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017;19(9):1242–1251.
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016;375:1834–1844.
- Ahrén B, Atkin SL, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin and/or thiazolidinediones in patients with type 2 diabetes. The Lancet Diabetes & Endocrinology. 2017.
- O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight management in patients with obesity: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138–150.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002.
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021;397:971–984.
- Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with overweight or obesity. Diabetes, Obesity and Metabolism. 2021;23(3):754–762.
- Davies M, Pieber TR, Hartoft-Nielsen ML, et al. Effect of Oral Semaglutide Compared With Placebo and Liraglutide on Body Weight in Patients With Type 2 Diabetes. Diabetes Care. 2019.
- Sorli C, Harashima S-I, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes. Diabetes Care. 2017.
- Pratley R, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The Lancet Diabetes & Endocrinology. 2018;6:275–286.
- Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes — state-of-the-art. Molecular Metabolism. 2021. Review used for broader physiological context; primary semaglutide studies above provide compound-specific evidence.
Bibliographic metadata, DOI information, PubMed identifiers, publication dates, and page ranges should be checked against the original publisher or PubMed record before final publication. Primary semaglutide studies should be distinguished from broader GLP-1 receptor agonist reviews when making compound-specific claims.